

F. No. 50014/03/2020-CDN
Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals

Shastri Bhawan, New Delhi
Dated: September, 2021

Subject: Monthly Summary Report in respect of Department of Pharmaceuticals for the month of August, 2021-reg.

The undersigned is directed to circulate herewith a copy of the Monthly Summary pertaining to the Department of Pharmaceuticals for the month of August, 2021 for information.



(Sandeep Kumar)

Under Secretary to the Govt. of India

To,

1. All members of Council of Ministers.
2. Vice Chairman, NITI Aayog, Yojana Bhawan, New Delhi.
3. The Principal information Officer, M/o Information and Broadcasting, Shastri Bhawan, New Delhi.

Copy to:

1. Secretaries to the Govt. of India, All Ministries/Department.
2. The Chairman, UPSC, Shahajahan Road, New Delhi-110069.
3. Secretary to President of India (Rashtrapati Ke Sachiv), Rashtrapati Bhawan, New Delhi-110004.
4. Secretary to Vice- President of India (Uprashtrapati Ke Sachiv), New Delhi-110004.
5. PS to Prime Minister of India, South Block, New Delhi-110004.
6. Director, Cabinet Secretariat, Rashtrapati Bhawan, New Delhi-110004.
7. PSO to Secretary (Pharma).
8. Director (NIC), Department of Pharmaceuticals, Shastri Bhawan, New Delhi.

Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals
Monthly Summary for the Month of August, 2021

Important events for the Month of **August, 2021** are as follows:

1. IMPORTANT POLICY DECISIONS:

(i) In pursuance to the directions of the Empowered Group – 2, Emergency Response Capabilities and in consultation with DoHFW, permission up to 18.08.2021 was accorded to DGFT for export of about 1.03 crore vials of Remdesivir.

(ii) Amendment made in Para 18 of DPCO, 2013 on 12.08.2021 for making revision in ceiling prices after every five years and de-linking the same with publication of NLEM, so as to bring predictability.

(iii) Pursuant to decision taken in the 3rd meeting of the National Medical Devices Promotion Council on 24.08.2021 under the co-chairmanship of Secretary DoP and Secretary DPIIT, a Standing Forum of Industry Associations of Medical Device Industry has been set up on 25.08.2021 to provide collated industry inputs to department on policy issues facing the Industry.

2. MAJOR ACHIEVEMENTS:

I. National Pharmaceutical Pricing Authority (NPPA):

(i) Retail prices of 25 new medicines have been fixed during August, 2021 bringing cumulative figure to 1598 till August, 2021

(ii) Total overcharged amount received during August, 2021 is Rs. 23.65 Lakhs.

II. Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP):

(i) 122 Jan Aushadhi Kendras under Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) were opened during August, 2021 across the country taking cumulative total to 8122.

(ii) Departmental Parliamentary Standing Committee visited Guwahati and Kolkata during the month to review the performance of the Scheme in the States.

III. National Institutes of Pharmaceutical Education and Research (NIPERs):

(i) 57 Research papers have been published in August, 2021.

(ii) Convocations of NIPER Raebareli, Hyderabad and Guwahati were held.

(iii) Online counselling was held for admission for academic session 2021 in seven NIPERs.

(iv) Rs. 46.00 crore has been released to NIPERs during the month of August, 2021.

(v) Departmental Parliamentary Standing Committee visited NIPER Guwahati and NIPER Kolkata during the month to review the performance of the Institutes.

IV. COVID-related activities:

(a) Control Room set up by NPPA received 1139 complaints for the period up to August, 2021. The issues raised were addressed and resolved, solutions provided or forwarded to concerned authorities for redressal and followed up.

(b) Coordination with States/UTs & manufacturers done and facilitation provided to monitor supplies for Buffer Stock Management of drugs used for COVID-19.

Market Research on availability of COVID Management Drugs:

NPPA through Price Monitoring and Resource Units (PMRUs) in the eighteen States conducted five (5) market research analysis on weekly basis in August, 2021 to assess the availability of COVID Management Drugs in the market.

V. Budget Expenditure:

In the Financial Year 2021-22, the total budget allocated to Department of Pharmaceuticals Rs. 470.41 Cr and the details of expenditure incurred are as below:

(Rs. in Crore)

Total Budget allocated	Expenditure incurred (as on 3.9.2021)	Expenditure incurred in the month of August, 2021
Rs. 470.41	Rs. 169.40	49.81

VI. Status of PLI Schemes:

S.No.	Name of Scheme	Total No. of application received	Total no. of application approved during the month of August, 2021	Total no. of application approved till date (31.08.2021)
1	Production Linked Incentive for Bulk Drugs	215	24 applications received in 2nd round by 31.08.2021	42 (from 1st round)
2	Production Linked Incentive for Medical Device	28	14 applications received in 2nd round by 31.08.2021	13 (from 1st round)
3	Production Linked Incentive scheme for Pharmaceuticals	The scheme was notified on 03.03.2021, Corrigendum issued 10.07.2021 & 22.07.2021 FAQs were issued on 01.07.2021	278 applications have been received under the scheme (closing date & 31.08.2021) which are under evaluation.	

VII Scheme for Assistance to Pharma Clusters

Second installment of Rs. 1.15 cr. released to M/s Kala Amb Infrastructure Development Company (KIDC)

3. The details of grievances during the **August, 2021** are as under:

No. of grievances at the start of the month	No. of grievances received during the month	No. of grievances disposed	No. of grievances pending at end of the month
74	125	149	50

4. FDI proposals: -

(a) Pending at beginning of the month	:-	16
(b) Received during the month	:-	2
(c) Disposed of during the month	:-	1
(d) Pending at end of the month	:-	17
